The Valley Desk

NCT02159053 · Interventional trial

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

Overall registry status Completed

Phase 3

Conditions Spondylitis, Ankylosing

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov